Patent intelligence · US
US 8563014
Modafinil oral lyophilizate
Modafinil oral lyophilizate
Patent details — US 8563014
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 22, 2013
- Expiration
- Oct 17, 2033
- Applicant
- Teva Sante
- Claims
- 14
- CPC classes
- A61K, A61K31/165, A61K9/0056, A61K9/2081
Quick answer
US 8563014 (Modafinil oral lyophilizate) is held by Teva Sante. Status: granted. Granted Oct 22, 2013. Expires Oct 17, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Sante
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/165, A61K9/0056, A61K9/2081, A61K9/2095, A61K9/5015
More from Teva Sante
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8563014?
US 8563014 (Modafinil oral lyophilizate) is held by Teva Sante. Status: granted. Granted Oct 22, 2013. Expires Oct 17, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8563014?
Teva Sante is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8563014 expire?
Our index shows an expiration date of Oct 17, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.